Treatment (reference) | N | Line | ORR (%) | mPFS (months) | mOS (months) |
|---|
Poziotinib [56] | 115 | ≥2 | 14.8 | 4.2 | NA |
Mobocertinib [57] | 114 | ≥2 | 28 | 7.2 | 24 |
Amivantamab [58] | 81 | ≥2 | 40 | 8.3 | 22.8 |
CLN-081 [59] | 42 | ≥2 | 31 | NA | NA |
DZD9008 [60] | 56 | ≥2 | 37.5 | NA | NA |
Furmonertinib [61] | 10 | ≥2 | 60 | NA | NA |
